Opthea (OPT) Appoints Kathy Connell to its Board

Go back to Opthea (OPT) Appoints Kathy Connell to its Board

Opthea Appoints Kathy Connell to Board of Directors

November 15, 2024 7:00 AM UTC

Ms. Connell is a commercial executive with business development expertise

Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025

MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, Opthea, the Company), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the Board) as a Non-Executive Director. Ms. Connells appointment was effective immediately after the... More